Prion diseases are serious, not curable neurodegenerative disorders caused by the accumulation of the misfolded protein PrP(Sc) that represents the pathological variant of the normally folded cellular protein PrP(C). Molecules that bind the cellular isoform PrP(C) preventing its misfolding, could arrest the progression of pathological conditions related to the abnormal PrP protein. In this context, by combining 3D-QSAR model, derived from pharmacophore-based alignment, with molecular docking procedures and physico-chemical properties prediction we have developed a virtual screening protocol to find novel chemicals able to prevent PrP(C) misfolding. We identified different hits characterized by low toxicity and able to inhibit PrP(Sc) accumulation in vitro in prion-infected neuroblastoma cell lines (ScN2a). In this assay, the pyrroloquinoxaline hydrazone 96 showed the higest potency with an IC50 value of 1.6 μM. Pyrroloquinoxaline 96 was demonstrated also to bind PrP(Sc) aggregates in infected ScN2a cells with a fluorescence pattern comparable to that found for Thioflavin-T. In consideration of its satisfactory physico-chemical properties, including predicted blood brain barrier permeability, 96 could represent an interesting prototypic hit for the development of diagnostic and therapeutic probes for prion diseases. © 2016 Elsevier Masson SAS
Zaccagnini, L., Brogi, S., Brindisi, M., Gemma, S., Chemi, G., Legname, G., et al. (2017). Identification of novel fluorescent probes preventing PrP(Sc) replication in prion diseases. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 127, 859-873 [10.1016/j.ejmech.2016.10.064].
Identification of novel fluorescent probes preventing PrP(Sc) replication in prion diseases
BRINDISI, MARGHERITA;GEMMA, SANDRA;CHEMI, GIULIA;CAMPIANI, GIUSEPPE;BUTINI, STEFANIA
2017-01-01
Abstract
Prion diseases are serious, not curable neurodegenerative disorders caused by the accumulation of the misfolded protein PrP(Sc) that represents the pathological variant of the normally folded cellular protein PrP(C). Molecules that bind the cellular isoform PrP(C) preventing its misfolding, could arrest the progression of pathological conditions related to the abnormal PrP protein. In this context, by combining 3D-QSAR model, derived from pharmacophore-based alignment, with molecular docking procedures and physico-chemical properties prediction we have developed a virtual screening protocol to find novel chemicals able to prevent PrP(C) misfolding. We identified different hits characterized by low toxicity and able to inhibit PrP(Sc) accumulation in vitro in prion-infected neuroblastoma cell lines (ScN2a). In this assay, the pyrroloquinoxaline hydrazone 96 showed the higest potency with an IC50 value of 1.6 μM. Pyrroloquinoxaline 96 was demonstrated also to bind PrP(Sc) aggregates in infected ScN2a cells with a fluorescence pattern comparable to that found for Thioflavin-T. In consideration of its satisfactory physico-chemical properties, including predicted blood brain barrier permeability, 96 could represent an interesting prototypic hit for the development of diagnostic and therapeutic probes for prion diseases. © 2016 Elsevier Masson SASFile | Dimensione | Formato | |
---|---|---|---|
Identification of novel fluorescent probes-Zaccagnini-2017.pdf
non disponibili
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
3.63 MB
Formato
Adobe PDF
|
3.63 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
CAMPIANI- Identification-PostPrint-EJMECH-revised.pdf
accesso aperto
Descrizione: Accepted Manuscript
Tipologia:
Post-print
Licenza:
Creative commons
Dimensione
2.24 MB
Formato
Adobe PDF
|
2.24 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/999896